Arcutis to Present at the 2021 Truist Securities Life Sciences Summit

Rhea-AI Summary

Arcutis Biotherapeutics, a late-stage biopharmaceutical firm focused on dermatological treatments, will participate in the 2021 Truist Securities Life Sciences Summit. The virtual fireside chat is scheduled for May 5, 2021, at 1:00 p.m. ET. Investors can access the presentation via Arcutis' website under the 'Events & Presentations' section. The company is developing therapies for various immune-mediated skin diseases and aims to enhance treatment options for conditions such as plaque psoriasis. An archived replay of the webcast will be available for 30 days post-conference.

WESTLAKE VILLAGE, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Arcutis management will participate in a virtual fireside chat during the 2021 Truist Securities Life Sciences Summit taking place May 4-5, 2021.

Details for the presentation are as follows:
        2021 Truist Securities Life Sciences Summit
        Fireside Chat Date: Wednesday, May 5, 2021
        Fireside Chat Time: 1:00 p.m. ET

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations. Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Arcutis - Bioscience, applied to the skin.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Investors and Media:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740

FAQ

What is the date for Arcutis' fireside chat at the Truist Securities Life Sciences Summit?

Arcutis' fireside chat is scheduled for May 5, 2021.

What time will Arcutis present at the Truist Securities Life Sciences Summit?

Arcutis will present at 1:00 p.m. ET on May 5, 2021.

Where can I watch the Arcutis presentation from the Truist Securities Life Sciences Summit?

The presentation can be accessed on Arcutis' website in the 'Events & Presentations' section.

How long will the Arcutis webcast be available after the summit?

The archived webcast will be available for 30 days after the conference.

What is the focus of Arcutis Biotherapeutics?

Arcutis focuses on developing treatments for unmet needs in immune-mediated dermatological diseases.